Locations:
Search IconSearch
October 8, 2019/Cancer

Palpable Masses Following Fat Grafting in Implant-Based Breast Reconstruction

Study reveals imaging not always necessary

19-PSX-3971-fatGrafting-650×450

Fat grafting has become an important tool in breast reconstruction, improving outcomes to such an extent that it is has become a standard practice. Along with the increasing popularity of fat grafting as part of breast reconstruction, a trend toward increased imaging and biopsies for palpable masses may be emerging. While some masses may indeed warrant further studies to test for malignancy, entertaining the possibility of cancer recurrence while undergoing invasive screening procedures may cause stress and anxiety in patients.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Some degree of palpable changes in fat grafted areas may be unavoidable, and is something that may not be communicated to patients or other clinicians who manage their follow-up after breast reconstruction. However, imaging and biopsies ordered in these situations tend to reveal benign changes, according to a recent Cleveland Clinic study of the incidence, type, timing and diagnostic yield of unexpected postsurgical imaging in women with implant-based breast reconstruction.

“As reconstructive surgeons perform fat grafting more frequently as part of reconstruction after mastectomy, we noticed what appeared to be an increasing tendency for clinicians to obtain imaging or biopsy during short and long term follow-up for cancer,” states Graham Schwarz, MD, a plastic surgeon with Cleveland Clinic’s Dermatology and Plastic Surgery Institute and senior author of the study. “We suspected that some of these tests, especially those ordered soon after surgery, may be potentially unnecessary and might increase patients’ anxiety, healthcare resource utilization and cost. We wanted to explore the timing, frequency and results of this testing, and which providers were ordering the tests, in order to develop provider and patient education focusing on what to expect following breast reconstruction with fat grafting.”

Palpable masses frequently the result of benign changes

Researchers reviewed the records of 166 patients (204 breasts) who underwent fat grafting as part of implant-based breast reconstruction. The most common diagnoses were invasive breast cancer (106 breasts) and ductal carcinoma in situ (52 breasts). The patients underwent a mean of 1.3 fat grafting episodes, and the average amount of fat transferred was 107.5 cc per breast, per episode. Of the group, 26.5% underwent at least one imaging study and 7.8% had at least one biopsy. Twenty-five women (15%) had mammography, 42 women (25.3) had at ultrasound imaging and three (1.8%) had magnetic resonance imaging (MRI).

Advertisement

Fat-related changes, such as fat necrosis or the development of oil cysts, were the most common findings. Although some of the imaging results were assessed as suspicious for malignancy, it is important to note that, in all these cases, biopsy of the suspicious masses was benign.

Imaging was ordered by multiple providers, including oncologists, medical/surgical breast specialists and primary care physicians. Plastic surgeons ordered imaging and biopsies with less frequency. Overall, the reconstructive teams were involved in diagnostic decision-making one-third of the time.

Educational opportunity

“One key takeaway from this study is that we have the opportunity to educate patients and providers alike about what to expect after fat grafting performed during the breast reconstruction process. Collaborating with our breast radiology colleagues, we developed an algorithmic approach to managing patients who present with a palpable mass following fat grafting procedures. Our next steps include developing a patient education plan that conveys information about safety and common postoperative physical findings, and encourages patients, when possible, to consult their reconstructive surgeons before undergoing additional imaging or biopsies. We also learned that reconstructive surgeons can help their clinical colleagues by providing more focused documentation about the anatomic region of fat grafting and where in the breast palpable nodules arise following the procedure,” Dr. Schwarz says.

“Overall, fat grafting in breast reconstruction after mastectomy is a procedure that significantly enhances reconstructive results. Data from multiple studies support the fact that it does not promote recurrence of breast cancer within the first years after surgery,” Dr. Schwarz continues. “Vigilance on the part of the patients and physicians is key to detecting recurrence. There were certainly multiple instances in which there was suspicion and additional testing was needed. However, if we can identify in which situations these tests will be of low yield, we can reduce the inconvenience and emotional burden of additional testing for breast cancer patients.”

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad